Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

• Main Authors: Li, F.-F, Gao, G, Li, Q, Zhu, H.-H, Su, X.-F, Wu, J.-D, Ye, L, Ma, J.-H
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: 8 isoprostaglandin F2 alpha; antidiabetic agent; dapagliflozin; glucose; metformin; placebo; 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; 8-epi-prostaglandin F2alpha; benzhydryl derivative; glucoside; glycosylated hemoglobin; hemoglobin A1c protein, human; prostaglandin F2 alpha; Article; blood glucose monitoring; clinical article; controlled study; data collection method; diabetic patient; diagnostic test accuracy study; double blind procedure; drug efficacy; drug safety; drug tolerability; glucose blood level; glycemic control; human; hyperglycemia; hypoglycemia; lifestyle modification; non insulin dependent diabetes mellitus; outcome assessment; oxidative stress; patient counseling; phase 3 clinical trial; plasma; prostaglandin blood level; randomized controlled trial; receiver operating characteristic; risk reduction; treatment duration; urinary tract infection; analogs and derivatives; clinical trial; metabolism; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Double-Blind Method; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Oxidative Stress
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183370
• Institution: National University of Singapore

10.1155/2016/5347262